A Flagship Pioneering Company
Resetting autoimmunity for cures. At scale.
Sail is building a new class of RNA medicines that act directly inside the body. We started with a pioneering approach to In Vivo CAR-T that is designed to deliver durable disease remission for patients at an unprecedented scale.
Pioneering In Vivo CAR-T at scale
By instructing immune cells to act directly inside the body, Sail aims to develop potentially curative medicines for millions of patients. Our integrated platform brings together Endless RNA™ (eRNA™) constructs and targeted nanoparticles (TNPs) to deliver eRNA-encoded and transiently-expressed protein cargos, including chimeric antigen receptors (CAR)to T-cells. Together, these technologies form the foundation for a modular product form capable of generating off-the-shelf life-changing CAR-T cell therapies for patients’ immune-mediated diseases.
01 
endless rna
Extended expression to drive therapeutic impact
Sail is pioneering eRNA, a translatable circular RNA designed to sustain protein expression inside the body. Its circular structure protects it from exonuclease degradation, creating an extended expression window that can improve dose efficiency and support powerful therapeutic activity far greater than mRNA.
02 Targeted Nanoparticles
Delivering at scale medicines to patients that can cure their disease
Sail’s targeted nanoparticles are designed to carry eRNA beyond the liver and into selected lymphoid tissues and immune cells. Targeting ligands on the nanoparticle surface recognize specific cell markers, enabling precise and efficient delivery and release of the eRNA payload inside the cell.
03 Integrated, Generated Design
Designed together as one medicine, powered by AI
eRNA and targeted nanoparticles are designed together to optimize expression, cell selectivity, tissue reach, dose efficiency, and manufacturability. This integrated approach enables Sail to create a new class of medicines that act inside the body.